Mycoplasma pneumoniae (MP) is a prokaryotic microorganism belonging to the family Mycoplasma, one of the smallest independently surviving prokaryotic organisms that does not possess a cell wall structure. Here are some key points about Mycoplasma pneumoniae:
1. Structural features: Mycoplasma pneumoniae is round, oval or filamentous, with a size of about 0.3 micrometers to 0.8 micrometers, and is naturally resistant to antibiotics, such as penicillin and cephalosporins, because it does not have a cell wall, which is one of the important differences between it and other bacterial infections.
2. Pathogenesis: Mycoplasma pneumoniae adheres to respiratory epithelial cells through its special terminal structure, releasing toxic metabolites and causing damage to host cells. It can cause a localized inflammatory reaction in the respiratory mucosa, which can further develop into bronchitis, pneumonia and other diseases.
3. Transmission: Mycoplasma pneumoniae is mainly transmitted through droplet transmission, e.g. tiny droplets discharged from coughing and sneezing contain Mycoplasma pneumoniae, which may be infected when inhaled by other people.
4. Disease manifestations: After infection with Mycoplasma pneumoniae, patients usually have fever, cough (especially dry cough), headache, fatigue, muscle pain, and loss of appetite. Lung lesions can be manifested as interstitial inflammation of the lungs, and infiltrating shadows of the lungs can be seen on chest X-ray or CT.
5. Diagnostic methods: Usually through serologic tests (such as condensation set test, complement binding test or enzyme-linked immunosorbent assay, etc.) to detect the changes in the level of antibodies to Mycoplasma pneumoniae in the patient’s body, or the use of molecular biology methods, such as PCR, to detect Mycoplasma pneumoniae nucleic acid in the sputum, nasopharyngeal swab specimens.
6. Preventive measures: As the vaccine for Mycoplasma pneumoniae is not yet available on the market, prevention focuses on strengthening the body’s immunity, maintaining good living habits, reducing the risk of exposure in places where people gather, and adopting appropriate respiratory hygiene measures during the epidemic season.
Note: Schematic structure of Mycoplasma
Mycoplasmas are similar to bacteria and also have a cellular structure, but no cell wall.
Diagnostic value
Mycoplasma pneumoniae antigen antibody test has important diagnostic value in clinical diagnosis and treatment:
– Antigen detection: detects the presence of antigenic components of Mycoplasma pneumoniae in the patient, such as membrane proteins and lipopolysaccharides of Mycoplasma pneumoniae, etc. It can be used for early and rapid diagnosis of Mycoplasma pneumoniae infection. When the infection is in its early stages and the pathogen is present in large quantities, the positive rate of antigen detection is relatively high, allowing rapid identification of the source of infection.
– Antibody testing: Detects Mycoplasma pneumoniae-specific antibodies, including IgM and IgG, in the patient’s blood. IgM antibodies appear earlier, usually starting to rise 1-3 weeks after infection, and serve as a marker of acute infection; IgG antibodies appear a little later but can persist for a longer period of time, reflecting previous or chronic infection. Detection of dynamic changes in IgG and IgM antibodies can assist in the diagnosis of current or previous Mycoplasma pneumoniae infections.
And antibody testing is currently the primary means of detecting Mycoplasma infections.
Product Menu
Product Description:Mycoplasma pneumoniae IgG/IgM Rapid Test Large Panel is a lateral flow immunochromatographic assay for the qualitative detection of Mycoplasma pneumoniae IgG/IgM in human serum, plasma or whole blood.
Type: Mycoplasma pneumoniae IgM Rapid Test, Mycoplasma pneumoniae IgG Rapid Test, Mycoplasma pneumoniae IgM/G Rapid Test
Product No.: RF0611, RF0821, RF0631
Sample type: WB/S/P
Product expiration date: 48 months
IVDMAPPER.COM
